President Donald Trump's pharmaceutical holdings reached a disclosed maximum of $56.2 million (€50 million and £42.3 million) in 2025, congressional Democrats said. They released their findings in Washington on Friday, 16 October 2026. The analysis raises questions about investments in companies whose medicines benefited from changes to Medicare pricing rules.
The White House denies any conflict of interest. Spokesperson Davis Ingle told the Associated Press that independent financial institutions manage Trump's investments without instructions from him or his family.
